<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Biotherapy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Biotherapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский биотерапевтический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9784</issn><issn publication-format="electronic">1726-9792</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1498</article-id><article-id pub-id-type="doi">10.17650/1726-9784-2024-23-4-77-82</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>BRIEF REPORT</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КРАТКОЕ СООБЩЕНИЕ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Experimental study of somatostatin analogue cyphetrylin lipophilicity</article-title><trans-title-group xml:lang="ru"><trans-title>Экспериментальное исследование липофильности аналога соматостатина цифетрилина</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3034-750X</contrib-id><name-alternatives><name xml:lang="en"><surname>Shprakh</surname><given-names>Z. S.</given-names></name><name xml:lang="ru"><surname>Шпрах</surname><given-names>З. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Zoya Sergeevna Shprakh</p><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>Зоя Сергеевна Шпрах</p><p>115522 Москва, Каширское шоссе, 24</p></bio><email>z.shprakh@ronc.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9200-4492</contrib-id><name-alternatives><name xml:lang="en"><surname>Ignateva</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Игнатьева</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Elena V. Ignateva</p><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7845-1651</contrib-id><name-alternatives><name xml:lang="en"><surname>Kraeva</surname><given-names>M. N.</given-names></name><name xml:lang="ru"><surname>Краева</surname><given-names>М. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Marina N. Kraeva</p><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8818-7812</contrib-id><name-alternatives><name xml:lang="en"><surname>Yartseva</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Ярцева</surname><given-names>И. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Irina V. Yartseva</p><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0218-8265</contrib-id><name-alternatives><name xml:lang="en"><surname>Gusev</surname><given-names>D. V.</given-names></name><name xml:lang="ru"><surname>Гусев</surname><given-names>Д. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dmitriy V. Gusev</p><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6740-5692</contrib-id><name-alternatives><name xml:lang="en"><surname>Dmitrieva</surname><given-names>M. V.</given-names></name><name xml:lang="ru"><surname>Дмитриева</surname><given-names>М. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Maria V. Dmitrieva</p><p>24 Kashirskoe Shosse, Moscow 115522</p></bio><bio xml:lang="ru"><p>115522 Москва, Каширское шоссе, 24</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-12-19" publication-format="electronic"><day>19</day><month>12</month><year>2024</year></pub-date><volume>23</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>77</fpage><lpage>82</lpage><history><date date-type="received" iso-8601-date="2024-12-19"><day>19</day><month>12</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-12-19"><day>19</day><month>12</month><year>2024</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://bioterapevt.abvpress.ru/jour/article/view/1498">https://bioterapevt.abvpress.ru/jour/article/view/1498</self-uri><abstract xml:lang="en"><p><bold>Background</bold>. Lipophilicity is a fundamental physicochemical property that determines the solubility and transport of a drug through biological membranes, as well as its behavior in the body. Lipophilicity also affects the ability of a drug to bind to plasma proteins and reach the corresponding receptors. The standard for drug lipophilicity experimental study is measuring the distribution between two immiscible phases – aqueous (water and buffer solutions) and hydrophobic (most often octanol).</p><p><bold>Aim.</bold> The experimental study of somatostatin analogue cyphetrylin lipophilicity in octanol/water system distribution test.</p><p><bold>Materials and methods.</bold> The lipophilicity of cyphetrylin, synthesized in the Laboratory of Chemical Synthesis of the N.N. Blokhin National Medical Research Center for Oncology of the Russian Ministry of Health, was studied in the octanol/water system; ethanol was used to study cyphetrylin spectral characteristics and its quantitative determination; shake flask method, UV-spectrometry.</p><p><bold>Results</bold>. The experimental assessment of cyphetrylin lipophilicity was carried out by shake flask method in a system of mutually saturated water and octanol 1:1. Since cyphetrylin is practically insoluble in water, the concentration of the drug in the octanol phase was determined by UV-spectrometry and the concentration in water was calculated by mass balance. Lipophilicity was expressed as the decimal logarithm of the concentration of cyphetrylin in the octanol phase to its concentration in the aqueous phase (logPo/w) ratio. The experimentally determined value of logPo/w was 1.14.</p><p><bold>Conclusion.</bold> The lipophilicity of cyphetrylin was studied experimentally by shake flask method as a parameter that determines the molecule probability to reach the biological target. The logPo/w value 1.14 in decimal logarithmic form indicates moderate lipophilicity of cyphetrylin, which exhibits antitumor activity when interacting with somatostatin receptors.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение.</bold> Липофильность – фундаментальное физико-химическое свойство, определяющее растворимость и транспорт лекарственного средства (ЛС) через биологические мембраны, а также его поведение в организме. Липофильность влияет на способность ЛС связываться с белками плазмы крови и достигать соответствующих рецепторов. Стандартом экспериментального определения липофильности ЛС является измерение распределения между двумя несмешивающимися фазами – водной (водой и буферными растворами) и гидрофобной (чаще всего октанолом).</p><p><bold>Цель исследования</bold> – экспериментальное изучение липофильности аналога соматостатина цифетрилина в тесте распределения в системе октанол/вода.</p><p><bold>Материалы и методы</bold>. Липофильность цифетрилина, синтезированного в лаборатории химического синтеза НМИЦ онкологии им. Н.Н. Блохина, изучали в системе октанол/вода; для изучения спектральных характеристик цифетрилина и его количественного определения использовали этанол; методы – встряхивание колбы, спектрометрия в ультрафиолетовой (УФ) области спектра.</p><p><bold>Результаты</bold>. Экспериментальную оценку липофильности цифетрилина проводили методом встряхивания колбы в системе взаимонасыщенных воды и октанола 1:1. Поскольку цифетрилин практически нерастворим в воде, определяли концентрацию ЛС в октанольной фазе методом УФ-спектрометрии и рассчитывали концентрацию в воде по балансу масс. Липофильность выражали как десятичный логарифм отношения концентрации цифетрилина в октанольной фазе к его концентрации в водной фазе (logPo/w). Определенное экспериментально значение logPo/w составило 1,14.</p><p><bold>Заключение</bold>. Липофильность цифетрилина определена экспериментально методом встряхивания колбы как параметр, определяющий вероятность достижения молекулой биологической мишени. Значение logPo/w составило 1,14 в десятичной логарифмической форме, что указывает на умеренную липофильность цифетрилина, проявляющего противоопухолевую активность при взаимодействии с рецепторами к соматостатину.</p></trans-abstract><kwd-group xml:lang="en"><kwd>lipophilicity</kwd><kwd>cyphetrylin</kwd><kwd>partition coefficient</kwd><kwd>1-octanol/water system</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>липофильность</kwd><kwd>цифетрилин</kwd><kwd>коэффициент распределения</kwd><kwd>система 1-октанол/вода</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The study was performed without external funding</funding-statement><funding-statement xml:lang="ru">Исследование проведено без спонсорской поддержки</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Wardecki D., Dołowy M., Bober-Majnusz K. Evaluation of the usefulness of topological indices for predicting selected physicochemical properties of bioactive substances with antiandrogenic and hypouricemic activity. Molecules 2023;28(15):5822. DOI: 10.3390/molecules28155822</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Kempińska D., Chmiel T., Kot-Wasik A. et al. State of the art and prospects of methods for determination of lipophilicity of chemical compounds. Trends Anal Chem 2019;113:54–73. DOI: 10.1016/j.trac.2019.01.011</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Arnott J.A., Planey S.L. The influence of lipophilicity in drug discovery and design. Expert Opin Drug Discov 2012;7(10): 863–75. DOI: 10.1517/17460441.2012.714363</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Broccatelli F., Aliagas I., Zheng H. Why decreasing lipophilicity alone is often not a reliable strategy for extending IV half-life. ACS Med Chem Lett 2018;9(6):522–7. DOI: 10.1021/acsmedchemlett.8b00047</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Amezqueta S., Subirats X., Fuguet E. et al. Chapter 6 – Octanol– Water Partition Constant. Editor C.F. Poole. In: Handbooks in Separation Science Liquid-Phase Extraction. Elsevier, 2020. P. 183–208. DOI: 10.1016/B978-0-12-816911-7.00006-2</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Sharapova A., Ol’khovich M., Blokhina S., Perlovich G.L. Experimental Examination of Solubility and Lipophilicity as Pharmaceutically Relevant Points of Novel Bioactive Hybrid Compounds. Molecules 2022;27(19):6504. DOI: 10.3390/molecules27196504</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Bahmani A., Saaidpour S., Rostami A. A simple, robust and efficient computational method for n-octanol/water partition coefficients of substituted aromatic drugs. Sci Rep 2017;7:5760. DOI:10.1038/s41598-017-05964-z</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Roy D., Patel C. Revisiting the use of quantum chemical calculations in LogPoctanol-water prediction. Molecules 2023;28(2):801. DOI: 10.3390/molecules28020801</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Ramli N.A.S., Rania H., Roslan N.A. et al. Evaluation of distribution and partition coefficients of levulinic acid in octanol-water system at 298.15 K. J Solution Chem 2024;53: 471–85. DOI: 10.1007/s10953-023-01345-5</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Santos A., Soares J.X., Cravo S. et al. Lipophilicity assessement in drug discovery: experimental and theoretical methods applied to xanthone derivatives. J Chromatogr B Analyt Technol Biomed Life Sci 2018;1072:182–92. DOI: 10.1016/j.jchromb.2017.10.018</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Katz D., Fike K., Longenberger J. et al. AlphaLogD determination: an optimized reversed-phase liquid chromatography method to measure lipophilicity on neutral and basic small and beyond-rule-of-five compounds. J Chromatogr A 2022;1674:463146. DOI: 10.1016/j.chroma.2022.463146</mixed-citation></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Smirnova L.I., Ustinkina S.V., Orlova O.L. et al. Drug with antitumor effect. RU2254139С1. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Смирнова Л.И., Устинкина С.В., Орлова О.Л. и др. Средство, обладающее противоопухолевым действием. Патент РФ № 2254139С1. 20.06.2005.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Shprakh Z.S., Yartseva I.V., Smirnova L.I. et al. Synthesis and chemico-pharmaceutical characteristics of a somatostatin analog with antitumor activity. Khimikofarmatsevticheskii zhurnal = Chemical and Pharmaceutical Journal 2012;48(3):19–22. (In Russ.) DOI: 10.30906/0023-1134-2014-48-3-19-22</mixed-citation><mixed-citation xml:lang="ru">Шпрах З.С., Ярцева И.В., Смирнова Л.И. и др. Синтез и химико-фармацевтические характеристики аналога соматостатина, обладающего противоопухолевой активностью. Химико-фармацевтический журнал 2012;48(3):19–22. DOI:10.30906/0023-1134-2014-48-3-19-22</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Shprakh Z.S., Borisova L.M., Kiseleva M.P., Smirnova Z.S. Preclinical study of cyphetrylin antitumor efficiency on experimental animal tumors. Eksperimental’naya i klinicheskaya farmakologiya = Experimental and clinical pharmacology 2019;48(3):19–22. (In Russ.). DOI: 10.30906/0869-2092-2019-82-8-27-31</mixed-citation><mixed-citation xml:lang="ru">Шпрах З.С., Борисова Л.М., Киселева М.П., Смирнова З.С. Доклиническое изучение противоопухолевой активности цифетрилина на экспериментальных опухолях животных. Экспериментальная и клиническая фармакология 2019;82(8):27–31. DOI: 10.30906/0869-2092-2019-82-8-27-31</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Shprakh Z.S. Analogue of the hypothalamic hormone cyphetrylin: preclinical study and the first experience of clinical use. Materials of the IVth St. Petersburg International Oncological Forum “White Nights”: report abstract. Saint Petersburg, 2018. P. 169. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Шпрах З.С. Аналог гипоталамического гормона цифетрилин: доклиническое изучение и первый опыт клинического применения. Материалы IV Петербургского международного онкологического форума «Белые ночи»: тез. докл. СПб., 2018. С. 169.</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Borisova L.M., Kiseleva M.P., Osipov V.N. Cyphetrylin cytotoxic analogues (report II). Rossijskij bioterapevticeskij zurnal = Russian Journal of Biotherapy. 2017;16(2):23–9. (In Russ.). DOI: 10.17650/1726-9784-2017-16-2-23-29</mixed-citation><mixed-citation xml:lang="ru">Борисова Л.М., Киселева М.П., Осипов В.Н. и др. Цитотоксические аналоги цифетрилина (сообщение II). Российский биотерапевтический журнал 2017;16(2):23–9. DOI: 10.17650/1726-9784-2017-16-2-23-29</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><mixed-citation>OECD, Test No. 107: Partition coefficient (n-octanol/water): Shake flask method. OECD Guidelines for the Testing of Chemicals, Sect. 1. URL: https://www.oecd-ilibrary.org. DOI: 10.1787/9789264069626-en</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Teerasong S., Wattanasin P., Wilairat P., Nacapricha D. A simple method based on one phase measurement for determination of the octanol-water partition coefficient of drugs. Chiang Mai J Sci 2015;42(3):691–8.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Mohsen-Nia M., Ebrahimabadi A.H., Niknahad B. Partition coefficient n-octanol/water of propranolol and atenolol at different temperatures: Experimental and theoretical studies. J Chem Thermodyn 2012;54:393–7. DOI: 10.1016/j.jct.2012.05.021</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Port A., Bordas M., Enrech R. et al. Critical comparison of shake-flask, potentiometric and chromatographic methods for lipophilicity evaluation (logP) of neutral, acidic, basic, amphoteric, and zwitterionic drugs. Eur J Pharm Sci 2018;122:331–40. DOI:10.1016/j.ejps.2018.07.010</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Shprakh Z. Formulation of somatostatin analog tablets using quality by design approach. J Appl Pharm Sci 2021;11(4):96–105. DOI: 10.7324/JAPS.2021.110412</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Virtual Computational Chemistry Laboratory. URL: https://vcclab.org</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Wolk O., Agbaria R., Dahan A. Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development. Drug Des Devel Ther 2014;24(8):1563–75. DOI: 10.2147/DDDT.S68909</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Morak-Młodawska B., Jeleń M., Martula E., Korlacki R. Study of lipophilicity and adme properties of 1,9-diazaphenothiazines with anticancer action. Int J Mol Sci 2023;24(8):6970. DOI: 10.3390/ijms24086970</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Alqahtani M.S., Kazi M., Alsenaidy M.A., Ahmad M.Z. Advances in oral drug delivery. Front Pharm 2021;12:618411. DOI: 10.3389/fphar.2021.618411</mixed-citation></ref></ref-list></back></article>
